Inappropriate use of progression-free survival in cancer drug approvals

BMJ. 2020 Mar 10;368:m770. doi: 10.1136/bmj.m770.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Approval*
  • Humans
  • Neoplasms / drug therapy*
  • Progression-Free Survival*
  • Quality of Life
  • Survival Analysis
  • United States
  • United States Food and Drug Administration / standards*

Substances

  • Antineoplastic Agents